LIVIVO - Search results -

Search results

Result 1 - 10 of total 31

Search options

Article ; Online: Herpetological records from the Abujao basin, central Peruvian Amazon

Crnobrna, Brian / Santa-Cruz Farfan, Roy / Gallegos, Cesar / López-Rojas, Jhon Jairo / Llanqui, Irbin B. / Panduro Pisco, Grober / Arbaiza, Angel Kelsen

Check List. 2023 July 03, v. 19, no. 4 p.433-465

2023

Abstract: The effort to uncover herpetofauna within the zone of influence of the Sierra del Divisor National Park has been focused on the northern reaches. The Abujao basin represents the Sierra del Divisor region well in an understudied area central to the ... ...

Abstract	The effort to uncover herpetofauna within the zone of influence of the Sierra del Divisor National Park has been focused on the northern reaches. The Abujao basin represents the Sierra del Divisor region well in an understudied area central to the Peruvian Amazon. We found 108 species of amphibians and squamate reptiles. Seven records extend ranges from the northern regions, while two records unite with southern regions (Madre De Dios and the Fitzcarrald Arc/Purus valley). There are higher levels of diversity attributable to land-cover units indicative of high terraces and hilly zones, as opposed to low hydromorphic habitats. Our new record for Pristimantis iiap Padial, Gagliardi-Urrutia, Chaparro & Gutiérrez, 2016 brings more resolution to this newly described species. We made observations of an unidentified species of blindsnake, which could represent a unique part of the fauna. Despite variations, we only uphold the presence of various subspecies of Micrurus annellatus Peters, 1871.
Keywords	Micrurus ; basins ; herpetofauna ; land cover ; national parks ; new species ; Amazonia
Language	English
Dates of publication	2023-0703
Size	p. 433-465.
Publishing place	Pensoft Publishers
Document type	Article ; Online
ZDB-ID	2252867-2
ISSN	1809-127X
ISSN	1809-127X
DOI	10.15560/19.4.433
Database	NAL-Catalogue (AGRICOLA)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Comparación productiva y de calidad en leche de vacas Holstein pastoreando en diferentes sistemas del trópico alto

Rojas, Jhon Edwin Hoyos / Arizala, Joaquín Angulo / Ledesma, Liliana Mahecha / Houwers, Hendrick Willem / Cerón Muñoz, Mario Fernando

Acta Agronomica

2021 Volume 70, Issue 1

Abstract: This study evaluated the effect of different grazing systems on yield and quality of milk in Holstein cows. Four silvopastoral systems (SP) were compared, as follows: kikuyo (Cenchrus clandestinus) and ryegrass (Lolium ssp) (R); ryegrass, tree marigold ( ... ...

Abstract	This study evaluated the effect of different grazing systems on yield and quality of milk in Holstein cows. Four silvopastoral systems (SP) were compared, as follows: kikuyo (Cenchrus clandestinus) and ryegrass (Lolium ssp) (R); ryegrass, tree marigold (Tithonia diversifolia) and alder (Alnus acuminata) (sspR); kikuyo, tree marigold and alder (sspK); and ryegrass, kikuyo, tree marigold and alder (sspRK). The response variables were daily milk traits: yield, (PL), lactose, (L), fat, (G), and protein, (P); milk constituents of protein (% P) and fat (% G), and milk urea nitrogen (MUN) of 60 holstein cows from 1 to 6 parities. We used mixed generalized additive models with smoothed semiparametric effect for days in lactation (DEL), fixed effects of SP, number of calvings, and the random effect of lactation. According to the results, the SspR system had higher PL, L, P, and G compared with the other systems (P < 0.05), demonstrating the potential of silvopastoral systems in the high tropics.
Keywords	Dairy cattle ; Milk quality ; Silvopastoral systems
Subject code	630
Language	Spanish
Publishing country	nl
Document type	Article ; Online
ZDB-ID	2260321-9
ISSN	2323-0118 ; 0120-2812
ISSN (online)	2323-0118
ISSN	0120-2812
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: No Changes in Human Immunodeficiency Virus (HIV) Suppression and Inflammatory Markers in Cerebrospinal Fluid in Patients Randomly Switched to Dolutegravir Plus Lamivudine (Spanish HIV/AIDS Research Network, PreEC/RIS 62).

Tiraboschi, Juan M / Rojas, Jhon / Zetterberg, Henrik / Blennow, Kaj / Niubo, Jordi / Gostner, Johanna / Navarro-Alcaraz, Antonio / Piatti, Camila / Fuchs, Dietmar / Gisslén, Magnus / Rigo-Bonnin, Raul / Martinez, Esteban / Podzamczer, Daniel

The Journal of infectious diseases

2022 Volume 223, Issue 11, Page(s) 1928–1933

Abstract: A major concern of human immunodeficiency virus (HIV) dual therapy is a potentially lower efficacy in viral reservoirs, especially in the central nervous system (CNS). We evaluated HIV RNA, neuronal injury, and inflammatory biomarkers and dolutegravir ( ... ...

Abstract	A major concern of human immunodeficiency virus (HIV) dual therapy is a potentially lower efficacy in viral reservoirs, especially in the central nervous system (CNS). We evaluated HIV RNA, neuronal injury, and inflammatory biomarkers and dolutegravir (DTG) exposure in cerebrospinal fluid (CSF) in patients switching to DTG plus lamivudine (3TC). All participants maintained viral suppression in plasma and CSF at week 48. We observed no increase in CSF markers of inflammation or neuronal injury. Median (interquartile range) total and unbound DTG in CSF were 7.3 (5.9-8.4) and 1.7 (1.2-1.9) ng/mL, respectively. DTG+3TC may maintain viral control without changes in inflammatory/injury markers within the CNS reservoir.
MeSH term(s)	Anti-HIV Agents/therapeutic use ; Biomarkers/cerebrospinal fluid ; Drug Substitution ; HIV Infections/drug therapy ; HIV-1 ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Humans ; Lamivudine/therapeutic use ; Oxazines/therapeutic use ; Piperazines/therapeutic use ; Pyridones/therapeutic use ; Viral Load
Chemical Substances	Anti-HIV Agents ; Biomarkers ; Heterocyclic Compounds, 3-Ring ; Oxazines ; Piperazines ; Pyridones ; Lamivudine (2T8Q726O95) ; dolutegravir (DKO1W9H7M1)
Language	English
Publishing date	2022-02-03
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	3019-3
ISSN	1537-6613 ; 0022-1899
ISSN (online)	1537-6613
ISSN	0022-1899
DOI	10.1093/infdis/jiaa645
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh II Zs.50: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 445: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study.

Blanco, José L / Rojas, Jhon / de Lazzari, Elisa / Inciarte, Alexy / Subirana, Mar / Callau, Pilar / Martinez-Rebollar, María / Laguno, Montserrat / Mallolas, Josep / de la Mora, Lorena / Torres, Berta / Gonzalez-Cordón, Ana / Martinez, Esteban

The Journal of antimicrobial chemotherapy

2022 Volume 77, Issue 7, Page(s) 1974–1979

Abstract: Background: Tenofovir disoproxil fumarate, particularly when given with a ritonavir-boosted PI, reduces bone mineral density (BMD) and increases bone turnover markers (BTMs). Ritonavir-boosted atazanavir plus lamivudine is a feasible simplified option. ... ...

Abstract	Background: Tenofovir disoproxil fumarate, particularly when given with a ritonavir-boosted PI, reduces bone mineral density (BMD) and increases bone turnover markers (BTMs). Ritonavir-boosted atazanavir plus lamivudine is a feasible simplified option. We evaluated whether switching from a triple ritonavir-boosted PI plus tenofovir disoproxil fumarate to a two-drug regimen of lamivudine plus ritonavir-boosted atazanavir would improve BMD. Methods: Single-arm pilot study. Virologically suppressed patients on tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted PI with low BMD, without previous resistance mutations and/or virological failure to study drugs were switched to 100/300 mg of ritonavir-boosted atazanavir plus 300 mg of lamivudine once daily. The primary endpoint was BMD change by DXA at Week 48. Results: There were 31 patients, 4 (13%) female, and median age was 40 years. Seven participants (22.5%) had osteoporosis. At 48 weeks, mean (SD) changes in spine and hip BMD were +0.01 (0.03) (P = 0.0239) and +0.013 (0.03) g/cm2 (P = 0.0046), respectively. Mean (SD) T-score changes were +0.1 (0.23) (P = 0.0089) and +0.25 (0.76) (P = 0.0197), respectively. N-telopeptide and urine tenofovir disoproxil fumarate toxicity markers showed significant improvements. One participant withdrew from the study and two were lost to follow-up. There were no virological failures, or serious or grade 3-4 adverse events. Conclusions: Switching from a tenofovir disoproxil fumarate plus ritonavir-boosted PI triple therapy to a lamivudine plus ritonavir-boosted atazanavir two-drug regimen in virologically suppressed HIV-infected adults with low BMD was safe, increased low BMD and reduced plasma markers of bone turnover and urine markers of tenofovir disoproxil fumarate toxicity over 48 weeks.
MeSH term(s)	Adult ; Anti-HIV Agents/therapeutic use ; Atazanavir Sulfate/therapeutic use ; Bone Diseases, Metabolic/chemically induced ; Bone Diseases, Metabolic/prevention & control ; Drug Substitution ; Emtricitabine/therapeutic use ; Female ; HIV Infections/complications ; HIV Infections/drug therapy ; HIV Protease Inhibitors/therapeutic use ; Humans ; Lamivudine/therapeutic use ; Male ; Pilot Projects ; Ritonavir/adverse effects ; Ritonavir/therapeutic use ; Tenofovir/adverse effects ; Tenofovir/therapeutic use
Chemical Substances	Anti-HIV Agents ; HIV Protease Inhibitors ; Lamivudine (2T8Q726O95) ; Atazanavir Sulfate (4MT4VIE29P) ; Tenofovir (99YXE507IL) ; Emtricitabine (G70B4ETF4S) ; Ritonavir (O3J8G9O825)
Language	English
Publishing date	2022-05-05
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	191709-2
ISSN	1460-2091 ; 0305-7453
ISSN (online)	1460-2091
ISSN	0305-7453
DOI	10.1093/jac/dkac137
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1197: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 124: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: PrEP program experience in a hospital HIV unit. Description of baseline user profile and identification of opportunities for improvement.

Laguno, Montserrat / Ugarte, Ainoa / Martinez-Rebollar, María / Sobrino, Yeray / Font, Guillermo / de Lazzari, Elisa / de la Mora, Lorena / Torres, Berta / Chivite, Iván / Riera, Josep / Ambrosioni, Juan / Inciarte, Alexy / Gonzalez-Cordon, Ana / Rojas, Jhon / Cordon, Encarna / Blanco, José Luis / Martinez, Esteban / Mallolas, Josep

Enfermedades infecciosas y microbiologia clinica (English ed.)

2022 Volume 41, Issue 1, Page(s) 24–28

Abstract: Introduction: Pre-Exposure Prophylaxis (PrEP) is a biomedical intervention to prevent HIV infection in seronegative people at high risk of becoming infected. This strategy was endorsed in October 2019 by the Spanish Ministry of Health.: Objective: To ...

Abstract	Introduction: Pre-Exposure Prophylaxis (PrEP) is a biomedical intervention to prevent HIV infection in seronegative people at high risk of becoming infected. This strategy was endorsed in October 2019 by the Spanish Ministry of Health. Objective: To present the PrEP initial experience in the HIV Unit of the Hospital Clínic of Barcelona, paying special attention to the analysis of the vulnerability factors in the cohort. Materials and methods: Retrospective, descriptive study. The epidemiological, sociodemographic, and clinical characteristics of the users included in the program during the first year are analyzed, paying particular attention to Infections, risky practices, and substance use. Results: 190 individuals were included, 177 men and 12 trans women with a mean age of 35 years (8 SD). 70% had higher education, and half had Spanish nationality. An average of 10 couples per trimester and 60% reported unprotected anal sex. 31% had at least one positive PCR for STIs, with N. gonorrhoeae being the most prevalent microorganism (51%) and the rectal sample the most affected (21%). 63% reported chemsex use, 19% polydrug use, and 8% "slamming". Half expressed concern about consumption and/or sexual practices and 25% the need for help. Conclusions: The PrEP user profile attended in our Hospital Unit justifies the creation of multidisciplinary teams that allow us to provide holistic attention to the sexual life of these people.
MeSH term(s)	Male ; Humans ; Female ; Adult ; HIV Infections/epidemiology ; HIV Infections/prevention & control ; Retrospective Studies ; Homosexuality, Male ; Substance-Related Disorders/epidemiology ; Hospital Units ; Hospitals
Language	English
Publishing date	2022-07-06
Publishing country	Spain
Document type	Journal Article ; Comment
ISSN	2529-993X
ISSN (online)	2529-993X
DOI	10.1016/j.eimce.2022.06.009
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Prolonged Effect of Zoledronic Acid on Bone Mineral Density and Turnover in HIV-Infected Adults on Tenofovir: A Randomized, Open-Label Study.

Carr, Andrew / Kerr, Stephen J / Richardson, Robyn / Ebeling, Peter / Pocock, Nicholas / Rojas, Jhon / Martinez, Esteban / Hoy, Jennifer

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

2019 Volume 34, Issue 12, Page(s) 2192–2197

Abstract: Zoledronic acid (ZOL) 5 mg annually was more effective than tenofovir disoproxil fumarate (TDF) switching at increasing bone mineral density (BMD) over 24 months in HIV-infected, osteopenic adults. To determine whether the effects of ZOL would persist ... ...

Abstract	Zoledronic acid (ZOL) 5 mg annually was more effective than tenofovir disoproxil fumarate (TDF) switching at increasing bone mineral density (BMD) over 24 months in HIV-infected, osteopenic adults. To determine whether the effects of ZOL would persist without further infusions, we compared changes in left hip and spine BMD over 36 months in participants randomized to ZOL 5 mg at baseline and month 12 (and to continue TDF) or to switch TDF (without receiving ZOL). We also compared changes in the plasma bone turnover markers (BTMs) C-terminal telopeptide of type 1 collagen (CTX; bone resorption), and procollagen type 1 N propeptide (P1NP; bone formation) and determined whether CTX and P1NP changes at month 3 predicted BMD changes at month 36. Changes were compared in the per-protocol populations, which included 32 (74%) of 43 participants randomized to ZOL and 37 (88%) of 42 participants who switched TDF. Despite not receiving ZOL after month 12, mean hip and spine BMD change from baseline were stable and remained greater with ZOL at month 36 than with TDF switching (spine: 7.5% versus 2.7%, mean difference 4.7%, p < 0.001; hip: 5.5% versus 1.5%, mean difference 4.0%, p < 0.001). CTX and P1NP levels declined in both groups but significantly more with ZOL. Only percent changes in P1NP at month 3 correlated inversely with BMD changes at month 36 (spine: rho = -0.442, p < 0.001; hip: rho = -0.373, p = 0.002). Two infusions of ZOL (in the presence of ongoing TDF) yielded sustained BMD increases through month 36 that remained greater than with TDF switching. © 2019 American Society for Bone and Mineral Research.
MeSH term(s)	Adult ; Biomarkers/blood ; Bone Density/drug effects ; Bone Remodeling/drug effects ; Female ; Fractures, Bone/complications ; Fractures, Bone/physiopathology ; HIV Infections/blood ; HIV Infections/drug therapy ; HIV Infections/physiopathology ; Humans ; Male ; Middle Aged ; Tenofovir/therapeutic use ; Treatment Outcome ; Zoledronic Acid/pharmacology
Chemical Substances	Biomarkers ; Zoledronic Acid (6XC1PAD3KF) ; Tenofovir (99YXE507IL)
Language	English
Publishing date	2019-10-24
Publishing country	United States
Document type	Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	632783-7
ISSN	1523-4681 ; 0884-0431
ISSN (online)	1523-4681
ISSN	0884-0431
DOI	10.1002/jbmr.3834
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2142: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV.

Hoy, Jennifer F / Richardson, Robyn / Ebeling, Peter R / Rojas, Jhon / Pocock, Nicholas / Kerr, Stephen J / Martinez, Esteban / Carr, Andrew

AIDS (London, England)

2018 Volume 32, Issue 14, Page(s) 1967–1975

Abstract: Objective: To compare the effects of switching tenofovir disoproxil fumarate (TDF) or treatment with an intravenous bisphosphonate on bone mineral density (BMD) in HIV-positive adults with low bone mass.: Design: Two-year, randomized, open-label ... ...

Abstract	Objective: To compare the effects of switching tenofovir disoproxil fumarate (TDF) or treatment with an intravenous bisphosphonate on bone mineral density (BMD) in HIV-positive adults with low bone mass. Design: Two-year, randomized, open-label study at 10 sites in Australia and Spain. Participants: Of 112 adults on TDF-based antiretroviral therapy (ART) screened, 87 with low BMD (T-score < -1.0 at hip or spine by dual-energy X-ray absorptiometry) and undetectable plasma HIV viral load were randomized to either switch TDF to another active antiretroviral drug or to continue TDF-based ART and receive intravenous zoledronic acid (ZOL) 5 mg annually for 2 years. Primary outcome measure: Change in lumbar spine BMD at 24 months by intention-to-treat analysis. Secondary outcomes included changes in femoral neck and total hip BMD, fractures, safety, and virological failure. Results: Forty-four participants were randomized to TDF switch and 43 to ZOL, mean age 50 years (SD 11), 96% men, mean TDF duration 5.9 years (SD 3.1), and mean spine and hip T-scores -1.6 and -1.3, respectively. At 24 months, mean spine BMD increased by 7.4% (SD 4.3%) with ZOL vs. 2.9% (SD 4.5%) with TDF-switch (mean difference 4.4%, 95% CI 2.6-6.3; P < 0.001). Mean total hip BMD increased by 4.6 (SD 2.6%) and 2.6% (SD 4%), respectively (mean difference 1.9%, 95% CI 0.5-3.4; P = 0.009). There was one fracture in the ZOL group vs. seven fractures in four TDF-switch participants. Virological failure occurred in one TDF-switch participant. Other safety endpoints were similar. Conclusion: ZOL is more effective than switching TDF at increasing BMD in HIV-positive adults with low bone mass.
MeSH term(s)	Absorptiometry, Photon ; Adult ; Aged ; Anti-HIV Agents/administration & dosage ; Australia ; Bone Density ; Bone Density Conservation Agents/administration & dosage ; Bone Diseases, Metabolic/prevention & control ; Drug Substitution ; Female ; Femur Neck/diagnostic imaging ; HIV Infections/complications ; Humans ; Lumbar Vertebrae/diagnostic imaging ; Male ; Middle Aged ; Spain ; Tenofovir/administration & dosage ; Treatment Outcome ; Viral Load ; Zoledronic Acid/administration & dosage
Chemical Substances	Anti-HIV Agents ; Bone Density Conservation Agents ; Zoledronic Acid (6XC1PAD3KF) ; Tenofovir (99YXE507IL)
Language	English
Publishing date	2018-06-20
Publishing country	England
Document type	Comparative Study ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	639076-6
ISSN	1473-5571 ; 0269-9370 ; 1350-2840
ISSN (online)	1473-5571
ISSN	0269-9370 ; 1350-2840
DOI	10.1097/QAD.0000000000001911
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2228: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Pharmacological developments obtained from marine natural products and current pipeline perspective.

Galeano, Elkin / Rojas, Jhon J / Martínez, Alejandro

Natural product communications

2011 Volume 6, Issue 2, Page(s) 287–300

Abstract: Marine organisms represent a new extensive source for bioactive molecules. They have the potential to provide new therapeutic alternatives to treat human diseases. In this paper, we describe and discuss a variety of isolated and semisynthetic molecules ... ...

Abstract	Marine organisms represent a new extensive source for bioactive molecules. They have the potential to provide new therapeutic alternatives to treat human diseases. In this paper, we describe and discuss a variety of isolated and semisynthetic molecules obtained from marine sources. These compounds are in phase II, phase III and at the commercialization stage of new drug development. A description of the mechanism of action, dosage used and side effects are also reported. The positive results obtained from these studies have triggered the development of new studies to evaluate the prospects for utilization of marine organisms.
MeSH term(s)	Animals ; Biological Products/isolation & purification ; Biological Products/pharmacology ; Drug Discovery ; Oceans and Seas
Chemical Substances	Biological Products
Language	English
Publishing date	2011-02
Publishing country	United States
Document type	Journal Article ; Review
ISSN	1934-578X
ISSN	1934-578X
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.

Rojas, Jhon / de Lazzari, Elisa / Negredo, Eugenia / Domingo, Pere / Tiraboschi, Juan / Ribera, Esteve / Abdulghani, Nadia / Puig, Jordi / Mateo, Maria G / Podzamczer, Daniel / Gutierrez, Maria M / Paredes, Roger / Clotet, Bonaventura / Gatell, Jose M / Blanco, Jose L / Martínez, Esteban

The lancet. HIV

2021 Volume 8, Issue 8, Page(s) e463–e473

Abstract: Background: Simplified antiretroviral therapy (ART) regimens are desirable for people with HIV. We investigated the efficacy and safety of switching from triple ART to dual dolutegravir plus lamivudine therapy.: Methods: DOLAM is a phase 4, ... ...

Abstract	Background: Simplified antiretroviral therapy (ART) regimens are desirable for people with HIV. We investigated the efficacy and safety of switching from triple ART to dual dolutegravir plus lamivudine therapy. Methods: DOLAM is a phase 4, randomised, open-label, non-inferiority trial, done at six HIV clinics in Catalonia, Spain. Adults with HIV-1 receiving a triple ART regimen, aged 18 years or older, with virological suppression, a CD4 nadir of at least 200 cells per μL, who were HBsAg-negative, and without previous viral failure or resistance mutations to study drugs were eligible. Participants underwent computer-generated randomisation, stratified by the class of the third drug, and were assigned (1:1) to switch to oral dolutegravir 50 mg and lamivudine 300 mg once daily or to continue triple ART for 48 weeks. The primary endpoint was the proportion of people with an HIV RNA value of at least 50 copies per mL at week 48 (US Food and Drug Administration snapshot algorithm, 8% non-inferiority margin). Both the primary and safety outcomes were evaluated in the intention-to-treat exposed population. The study is completed and was registered with EudraCT 201500027435. Findings: Between July 7, 2015, and Oct 31, 2018, 265 participants were randomly assigned to switch to dolutegravir plus lamivudine (n=131) or to maintain triple ART (n=134) and all received at least one dose. Nine (7%) participants in the dual therapy group and ten (7%) in the triple therapy group were excluded before 48 weeks, mostly due to treatment discontinuations or virological failure. Participants were predominantly male (116 [87%] of 134 in the triple ART group and 111 [85%] of 131 in the dolutegravir plus lamivudine group). The difference in the proportion of participants with HIV RNA values of at least 50 copies per mL at 48 weeks between the dual therapy group (three [2%] of 131) and triple therapy group (two [1%] of 134) was 0·8 percentage points (95% CI -3·3 to 5·2), showing non-inferiority of dolutegravir plus lamivudine dual therapy compared with triple ART. 73 (56%) of 131 participants allocated to dual therapy had 150 adverse effects, compared with 78 (58%) of 134 participants allocated to triple therapy who also had 150 adverse events (p=0·68). Drug discontinuation due to adverse effects occurred in four people in the triple therapy group and three people in the dual therapy group. Interpretation: Our findings show the efficacy and safety of dolutegravir plus lamivudine as a simplified therapy switch option for selected people with HIV with virological suppression on triple ART. Funding: Instituto de Salud Carlos III, Red de Investigación en Sida, and ViiV Healthcare.
MeSH term(s)	Adult ; Anti-HIV Agents/adverse effects ; Anti-HIV Agents/therapeutic use ; Cholesterol, HDL/blood ; Drug Therapy, Combination ; Female ; HIV Infections/drug therapy ; HIV Infections/virology ; Heterocyclic Compounds, 3-Ring/administration & dosage ; Heterocyclic Compounds, 3-Ring/adverse effects ; Humans ; Lamivudine/administration & dosage ; Lamivudine/adverse effects ; Male ; Middle Aged ; Oxazines/administration & dosage ; Oxazines/adverse effects ; Piperazines/administration & dosage ; Piperazines/adverse effects ; Pyridones/administration & dosage ; Pyridones/adverse effects
Chemical Substances	Anti-HIV Agents ; Cholesterol, HDL ; Heterocyclic Compounds, 3-Ring ; Oxazines ; Piperazines ; Pyridones ; Lamivudine (2T8Q726O95) ; dolutegravir (DKO1W9H7M1)
Language	English
Publishing date	2021-08-03
Publishing country	Netherlands
Document type	Clinical Trial, Phase IV ; Comparative Study ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ISSN	2352-3018
ISSN (online)	2352-3018
DOI	10.1016/S2352-3018(21)00100-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: PrEP program experience in a hospital HIV unit. Description of baseline user profile and identification of opportunities for improvement.

Laguno, Montserrat / Ugarte, Ainoa / Martinez-Rebollar, María / Sobrino, Yeray / Font, Guillermo / de Lazzari, Elisa / de la Mora, Lorena / Torres, Berta / Chivite, Iván / Riera, Josep / Ambrosioni, Juan / Inciarte, Alexy / González-Cordón, Ana / Rojas, Jhon / Cordón, Encarna / Blanco, José Luis / Martínez, Esteban / Mallolas, Josep

Enfermedades infecciosas y microbiologia clinica (English ed.)

2021

Title translation	Experiencia de un programa de profilaxis preexposición en una unidad de virus de la inmunodeficiencia humana hospitalaria. Descripción del perfil basal del usuario e identificación de oportunidades de mejora.
Abstract	Introduction: Pre-Exposure Prophylaxis (PrEP) is a biomedical intervention to prevent HIV infection in seronegative people at high risk of becoming infected. This strategy was endorsed in October 2019 by the Spanish Ministry of Health. Objective: To present the PrEP initial experience in the HIV Unit of the Hospital Clínic of Barcelona, paying special attention to the analysis of the vulnerability factors in the cohort. Materials and methods: Retrospective, descriptive study. The epidemiological, sociodemographic, and clinical characteristics of the users included in the program during the first year are analyzed, paying particular attention to Infections, risky practices, and substance use. Results: 190 individuals were included, 177 men and 12 trans women with a mean age of 35 years (8 SD). 70% had higher education, and half had Spanish nationality. An average of 10 couples per trimester and 60% reported unprotected anal sex. 31% had at least one positive PCR for STIs, with N. gonorrhoeae being the most prevalent microorganism (51%) and the rectal sample the most affected (21%). 63% reported chemsex use, 19% polydrug use, and 8% "slamming". Half expressed concern about consumption and/or sexual practices and 25% the need for help. Conclusions: The PrEP user profile attended in our Hospital Unit justifies the creation of multidisciplinary teams that allow us to provide holistic attention to the sexual life of these people.
Language	Spanish
Publishing date	2021-05-24
Publishing country	Spain
Document type	Journal Article
ISSN	2529-993X
ISSN (online)	2529-993X
DOI	10.1016/j.eimc.2021.04.005
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED